Home
    • Plans Blog Contact
    Charles River Laboratories logo

    Charles River Laboratories

    CRL
    Last price US$280.05
    Market cap US$11.3b
    12M price change 79.12%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Charles River Laboratories Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Mode Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Charles River Laboratories into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Revenue was $1B (reported); EPS was $3.05 (reported).

    Revenue $1B reported
    EPS $3.05 reported
    Operating income $119.9M +20% YoY
    Net income $52.3M reported

    What changed

    • Revenue reported to $1B; EPS reported to $3.05.
    • Operating income +20% YoY to $119.9M.

    Guidance / outlook

    the Company expects the second-quarter investment gains associated with the deferred compensation plan will be largely offset by a higher tax rate, resulting in a negligible net impact to non-GAAP earnings per share.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Aug 05, 2026 SEC filing 10-Q Aug 05, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 Earnings release Earnings release May 07, 2026 SEC filing 10-K Feb 18, 2026 SEC filing 8-K Feb 18, 2026 Earnings release Earnings release Feb 18, 2026 SEC filing 8-K Jan 13, 2026 SEC filing 10-Q Nov 05, 2025 SEC filing 8-K Nov 05, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Charles River Laboratories boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 2.49/5
    Charles River Laboratories exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Charles Rive... CRL US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.73/5
    Charles River Laboratories commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Charles Rive... CRL US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 1.61/5
    Charles River Laboratories registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Charles Rive... CRL US$11.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Charles River Laboratories logo

    Charles River Laboratories

    US$280.05

    US$141.38

    -49.5% vs price

    US$11.3b

    5.15%

    79.12%